Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 6/20 | 0.54 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.54 |
| ▸ | CDC25B | P30305 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769021 | 0.88 | TNKS (0.64) | TNKSCASP3SENP7CDC25BKDM4E | |
| SCHEMBL4766308 | 0.79 | GUSB (0.60) | TNKSCASP3SENP7CDC25BKDM4E | |
| SCHEMBL828493 | 0.79 | TNKS (0.63) | TNKSCASP3SENP7CDC25BKDM4E | |
| SCHEMBL29639160 | 0.79 | TNKS (0.63) | TNKSCASP3SENP7CDC25BKDM4E | |
| SCHEMBL1536353 | 0.78 | KDM4E (0.64) | TNKSCASP3SENP7KDM4EPARP1 | |
| SCHEMBL11661055 | 0.78 | KDM4E (0.76) | CASP3SENP7KDM4EGAASENP8 | |
| SCHEMBL30160687 | 0.78 | TNKS (0.58) | TNKSKDM4EGAAALDH1A1HPGD | |
| SCHEMBL28924649 | 0.78 | TNKS (0.58) | TNKSKDM4EGAAALDH1A1HPGD | |
| SCHEMBL4774288 | 0.77 | CDC25B (0.60) | TNKSCASP3SENP7CDC25BKDM4E | |
| SCHEMBL4771998 | 0.77 | CDC25B (0.57) | TNKSCASP3SENP7CDC25BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | TNKS 2508/4885CASP3 1930/4885SENP7 1267/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | TNKS 2461/4885CASP3 1203/4885SENP7 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.